References
- WHO: Public Health Imperative, E-book ed. 2019;1. Available from:
https://apps.who.int/iris/rest/bitstreams/1235662/retrieve - WHO: Atlas: Country resources for neurological disorders. 2017, 175–178 p. Available from:
https://apps.who.int/iris/rest/bit-streams/1088639/retrieve - Campbell M., McKenzie J.E., Sowden A., Katikireddi S.V., Brennan S.E., Ellis S. et al.: Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. BMJ, 2020, 368: 1–6. doi: 10.1136/bmj.l6890.
- Costa T., Fernandez-Villalba E., Izura V., Lucas-Ochoa A., Menezes-Filho N., Santana R. et al.: Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice. J. Neuroimmune Pharmacol., 2021, 16: 390–402. doi: 10.1007/s11481-020-09925-8
- Durankuş F., Şenkal E., Sünnetçi E., Albayrak Y., Beyazyüz M., Atasoy Ö. et al.: Beneficial Effects of Ibuprofen on Pentylenetetrazol-induced Convulsion. Neurochem. Res., 2020, 45: 2409–2416. doi: 10.1007/s11064-020-03101-3
- Goodman L.S., Gilman A. In: Goodman & Gillman’s The Pharmacological Basis of Therapeutics. E-book 13th ed. Brunton L.L., Hilal-Dandan R., Knollmann B.C. (eds.) McGraw-Hill Education, 2018.
- Hooijmans C.R, Rovers M.M., De Vries R.B.M., Leenaars M., Ritskes-Hoitinga M., Langendam M.W.: SYRCLE’s risk of bias tool for animal studies. BMC Med. Res. Methodol., 2014, 14: 1–9. doi: 10.1186/1471-2288-14-43
- Khansari P.S., Coyne L.: NSAIDs in the treatment and/or prevention of neurological disorders. Inflammopharmacology Jun., 2012 p. 159–167. doi: 10.1007/s10787-011-0116-2
- Liu R., Wu S., Guo C., Hu Z., Peng J., Guo K. et al.: Ibuprofen Exerts Antiepileptic and Neuroprotective Effects in the Rat Model of Pentylenetetrazol-Induced Epilepsy via the COX-2/NLRP3/IL-18 Pathway. Neurochem. Res., 2020, 45: 2516–2256. doi: 10.1007/s11064-020-03109-9
- Page M.J,. McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D. et al.: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021, 372. doi: 10.1136/bmj.n71
- Peng J., Wu S., Guo C., Guo K., Zhang W., Liu R. et al.: Effect of Ibuprofen on Autophagy of Astrocytes During Pentylenetetrazol-Induced Epilepsy and its Significance: An Experimental Study. Neurochem. Res., 2019, 44: 2566–2576. doi: 10.1007/s11064-019-02875-5
- Rawat C., Kukal S., Dahiya U.R., Kukreti R.: Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. J. Neuroinflammation, 2019, 16: 197. doi: /10.1186/s12974-019-1592-3.
- Roberts M.K., Chaney S.: Heparin-induced Thrombocytopenia. J. Nurse Pract., 2018, 14: 402–408.e3. doi: 10.1016/j.nurpra.2018.02.007
- Vezzani A., Balosso S,. Ravizza T. :Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat. Rev. Neurol., 2019, 15: 459–472. doi: 10.1038/s41582-019-0217-x
- Zhang C., Qin H., Zheng R., Wang Y., Yan T., Huan F. et al.: A new approach for Alzheimer’s disease treatment through P-gp regulation via ibuprofen. Pathol. Res. Pract., 2018, 214: 1765–1771. doi: 10.1016/j.prp.2018.08.011